{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T04:22:04Z","timestamp":1787631724936,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T00:00:00Z","timestamp":1508976000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s12325-017-0628-2","type":"journal-article","created":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T10:25:35Z","timestamp":1509013535000},"page":"2452-2465","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis"],"prefix":"10.1007","volume":"34","author":[{"given":"Nicholas J.","family":"Vogelzang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumanta K.","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8555-6363","authenticated-orcid":false,"given":"Sameer R.","family":"Ghate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyse","family":"Swallow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda","family":"Peeples","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam L.","family":"Zichlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark K.","family":"Meiselbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Ricardo","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,26]]},"reference":[{"key":"628_CR1","unstructured":"American Cancer Society. Key statistics about kidney cancer. http:\/\/www.cancer.org\/cancer\/kidney-cancer\/about\/key-statistics.html (2017). Accessed 20 Jan 2017."},{"issue":"1","key":"628_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3322\/caac.21166","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11\u201330.","journal-title":"CA Cancer J Clin"},{"key":"628_CR3","unstructured":"American Society of Clinical Oncology. Kidney cancer: risk factors and prevention. http:\/\/www.cancer.net\/cancer-types\/kidney-cancer\/risk-factors-and-prevention (2016). Accessed 20 Jan 2017."},{"key":"628_CR4","unstructured":"Chittoria N, Rini BI. Renal cell carcinoma. http:\/\/www.clevelandclinicmeded.com\/medicalpubs\/diseasemanagement\/nephrology\/renal-cell-carcinoma\/ (2013). Accessed 20 Jan 2017."},{"issue":"17","key":"628_CR5","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1001\/jama.281.17.1628","volume":"281","author":"WH Chow","year":"1999","unstructured":"Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States. JAMA. 1999;281(17):1628\u201331.","journal-title":"JAMA"},{"key":"628_CR6","doi-asserted-by":"crossref","unstructured":"Nguyen MM, Gill IS, Ellison LM. The evolving presentation of renal carcinoma in the United States: trends from the Surveillance, Epidemiology, and End Results program. J Urol. 2006;176(6 Pt 1):2397\u2013400; discussion 2400.","DOI":"10.1016\/j.juro.2006.07.144"},{"issue":"9669","key":"628_CR7","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736(09)60229-4","volume":"373","author":"BI Rini","year":"2009","unstructured":"Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373(9669):1119\u201332.","journal-title":"Lancet"},{"issue":"18","key":"628_CR8","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1093\/jnci\/djj362","volume":"98","author":"JM Hollingsworth","year":"2006","unstructured":"Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst. 2006;98(18):1331\u20134.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"628_CR9","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","volume":"28","author":"CN Sternberg","year":"2010","unstructured":"Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061\u20138.","journal-title":"J Clin Oncol"},{"issue":"2","key":"628_CR10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115\u201324.","journal-title":"N Engl J Med"},{"issue":"8","key":"628_CR11","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1303989","volume":"369","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722\u201331.","journal-title":"N Engl J Med"},{"key":"628_CR12","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ejca.2016.06.016","volume":"65","author":"JM Ruiz-Morales","year":"2016","unstructured":"Ruiz-Morales JM, Swierkowski M, Wells JC, Fraccon AP, Pasini F, Donskov F, et al. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Journal of Cancer. 2016;65:102\u20138.","journal-title":"Eur Journal of Cancer."},{"issue":"4","key":"628_CR13","doi-asserted-by":"publisher","first-page":"e573","DOI":"10.1016\/j.clgc.2016.12.005","volume":"15","author":"SK Pal","year":"2017","unstructured":"Pal SK, Ghate S, Li N, Swallow E, Peeples M, Zichlin ML, Perez JR, Agarwal N, Vogelzang NJ. Real-world survival outcomes and prognostic factors among patients receiving first targeted therapy for advanced renal cell carcinoma: a SEER-Medicare database analysis. Clin Genitourin Cancer. 2017;15(4):e573\u201382.","journal-title":"Clin Genitourin Cancer."},{"issue":"3\u20134","key":"628_CR14","doi-asserted-by":"publisher","first-page":"112","DOI":"10.5489\/cuaj.4398","volume":"11","author":"AA Lalani","year":"2017","unstructured":"Lalani AA, Li H, Heng DYC, Wood L, Kalirai A, Bjarnason GA, et al. First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience. Can Urol Assoc J. 2017;11(3\u20134):112\u20137.","journal-title":"Can Urol Assoc J"},{"key":"628_CR15","unstructured":"Galvis V, Chow, S., Lawrence, D., Hawkins, R. Clinical practice outcomes of patients treated with pazopanib for metastatic renal cell cancer (mRCC)\u20146\u00a0year experience at a referral centre in Manchester, UK. Eur J Cancer. 2013;49(Suppl 2):abstr 2763."},{"issue":"14","key":"628_CR16","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1200\/JCO.2013.50.8267","volume":"32","author":"B Escudier","year":"2014","unstructured":"Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol. 2014;32(14):1412\u20138.","journal-title":"J Clin Oncol"},{"key":"628_CR17","doi-asserted-by":"crossref","unstructured":"Delea TE, Amdahl J, Diaz J, Nakhaipour HR, Hackshaw MD. Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States. J Manag Care Spec Pharm. 2015;21(1):46\u201354.","DOI":"10.18553\/jmcp.2015.21.1.46"},{"key":"628_CR18","doi-asserted-by":"crossref","unstructured":"Hansen RN, Hackshaw MD, Nagar SP, Arondekar B, Deen KC, Sullivan SD, et al. Health care costs among renal cancer patients using pazopanib and sunitinib. J Manag Care Spec Pharm. 2015;21(1):37\u201344.","DOI":"10.18553\/jmcp.2015.21.1.37"},{"issue":"10","key":"628_CR19","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1185\/03007995.2015.1081881","volume":"31","author":"PN Racsa","year":"2015","unstructured":"Racsa PN, Whisman TR, Worley K. Comparing two tyrosine kinase inhibitors for treatment of advanced renal cell carcinoma in Medicare and commercially insured patients. Curr Med Res Opin. 2015;31(10):1933\u201340.","journal-title":"Curr Med Res Opin"},{"key":"628_CR20","unstructured":"Surveillance Epidemiology and End Results Program. Cancer stat facts: kidney and renal pelvis cancer. 2017. https:\/\/seer.cancer.gov\/statfacts\/html\/kidrp.html . Accessed 31 Oct 2016."},{"issue":"5","key":"628_CR21","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"issue":"11","key":"628_CR22","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130\u20139.","journal-title":"Med Care"},{"key":"628_CR23","unstructured":"US Bureau of Labor Statistics. Consumer price index (CPI)- medical care component. http:\/\/www.bls.gov\/cpi\/ (2015). Accessed 20 Sep 2016."},{"key":"628_CR24","doi-asserted-by":"crossref","unstructured":"Vogelzang N, Ghate S, Li N, Swallow E, Peeples M, Zichlin M, et al. Real-world outcomes among patients who initiated pazopanib or sunitinib as first targeted therapy for advanced renal cell carcinoma (aRCC): a retrospective analysis of Medicare data. Paper presented at the ISPOR 22nd annual international meeting, Boston, 20\u201324 May, 2017.","DOI":"10.1200\/JCO.2017.35.6_suppl.475"},{"issue":"3","key":"628_CR25","first-page":"50","volume":"7","author":"Y Neustadt","year":"2008","unstructured":"Neustadt Y, Pieczenik S. Organ reserve and healthy ageing. Integr Med. 2008;7(3):50\u20132.","journal-title":"Integr Med"},{"issue":"5","key":"628_CR26","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/bjc.2013.832","volume":"110","author":"TE Hutson","year":"2014","unstructured":"Hutson TE, Bukowski RM, Rini BI, Gore ME, Larkin JM, Figlin RA, et al. Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma. Br J Cancer. 2014;110(5):1125\u201332.","journal-title":"Br J Cancer"},{"issue":"4","key":"628_CR27","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/j.1464-410X.2006.06015.x","volume":"97","author":"N Berdjis","year":"2006","unstructured":"Berdjis N, Hakenberg OW, Novotny V, Froehner M, Wirth MP. Treating renal cell cancer in the elderly. BJU Int. 2006;97(4):703\u20135.","journal-title":"BJU Int"},{"key":"628_CR28","doi-asserted-by":"crossref","unstructured":"van den Brom RRH, van Es SC, Leliveld AM, Gietema JA, Hospers GAP, de Jong IJ, et al. Balancing treatment efficacy, toxicity and complication risk in elderly patients with metastatic renal cell carcinoma. Cancer Treat Rev. 2016;46(Suppl C):63\u201372.","DOI":"10.1016\/j.ctrv.2016.04.002"},{"issue":"18","key":"628_CR29","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1056\/NEJMc1400731","volume":"370","author":"RJ Motzer","year":"2014","unstructured":"Motzer RJ, Hutson TE, McCann L, Deen K, Choueiri TK. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med. 2014;370(18):1769\u201370.","journal-title":"N Engl J Med"},{"key":"628_CR30","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3389\/fphar.2017.00329","volume":"8","author":"C Porta","year":"2017","unstructured":"Porta C, Ferrari A, Czarnecka AM, Szczylik CA. Pazopanib in patients with clear-cell renal cell carcinoma: seeking the right patient. Front Pharmacol. 2017;8:329.","journal-title":"Front Pharmacol."},{"issue":"7","key":"628_CR31","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/annonc\/mdv030","volume":"26","author":"S Kalra","year":"2015","unstructured":"Kalra S, Rini BI, Jonasch E. Alternate sunitinib schedules in patients with metastatic renal cell carcinoma. Ann Oncol. 2015;26(7):1300\u20134.","journal-title":"Ann Oncol"},{"issue":"6","key":"628_CR32","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1002\/cam4.302","volume":"3","author":"C Porta","year":"2014","unstructured":"Porta C, Levy A, Hawkins R, Castellano D, Bellmunt J, Nathan P, et al. Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries. Cancer Med. 2014;3(6):1517\u201326.","journal-title":"Cancer Med"},{"issue":"14","key":"628_CR33","doi-asserted-by":"publisher","first-page":"3961","DOI":"10.1158\/1078-0432.CCR-12-0002","volume":"18","author":"AW Griffioen","year":"2012","unstructured":"Griffioen AW, Mans LA, de Graaf AM, Nowak-Sliwinska P, de Hoog CL, de Jong TA, et al. Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients. Clin Cancer Res. 2012;18(14):3961\u201371.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"628_CR34","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1093\/annonc\/mds431","volume":"24","author":"A Brunello","year":"2013","unstructured":"Brunello A, Basso U, Sacco C, Sava T, De Vivo R, Camerini A, et al. Safety and activity of sunitinib in elderly patients (\u226570\u00a0years) with metastatic renal cell carcinoma: a multicenter study. Ann Oncol. 2013;24(2):336\u201342.","journal-title":"Ann Oncol"},{"issue":"7","key":"628_CR35","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/annonc\/mdv030","volume":"26","author":"S Kalra","year":"2015","unstructured":"Kalra S, Rini BI, Jonasch E. Alternate sunitinib schedules in patients with metastatic renal cell carcinoma. Ann Oncol. 2015;26(7):1300\u20134.","journal-title":"Ann Oncol"},{"issue":"9807","key":"628_CR36","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","volume":"378","author":"BI Rini","year":"2011","unstructured":"Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931\u20139.","journal-title":"Lancet"},{"issue":"8","key":"628_CR37","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1200\/JCO.2013.50.3961","volume":"32","author":"TE Hutson","year":"2014","unstructured":"Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014;32(8):760\u20137.","journal-title":"J Clin Oncol"},{"issue":"8","key":"628_CR38","doi-asserted-by":"publisher","first-page":"979","DOI":"10.18553\/jmcp.2016.22.8.979","volume":"22","author":"E MacLean","year":"2016","unstructured":"MacLean E, Mardekian J, Cisar LA, Hoang CJ, Harnett J. Real-world treatment patterns and costs for patients with renal cell carcinoma initiating treatment with sunitinib and pazopanib. J Manag Care Spec Pharm. 2016;22(8):979\u201390.","journal-title":"J Manag Care Spec Pharm."},{"key":"628_CR39","doi-asserted-by":"crossref","unstructured":"Capri S, Porta C, Delea TE. Cost-effectiveness of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma from an Italian national health service perspective. Clin Ther. 2017;39(3):567\u201380.e2.","DOI":"10.1016\/j.clinthera.2017.01.017"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-017-0628-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-017-0628-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-017-0628-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T14:25:23Z","timestamp":1659709523000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-017-0628-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,26]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["628"],"URL":"https:\/\/doi.org\/10.1007\/s12325-017-0628-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,26]]},"assertion":[{"value":"30 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2017","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}